Cognition Therapeutics (CGTX) Earnings Date & Reports

Key Takeaways

• Cognition Therapeutics reported a third quarter 2026 net loss of $4.1 million, or $(0.04) per share, beating the $(0.07) per share consensus estimate.
• Research and development (R&D) expenses rose to $5.1 million, while general and administrative (G&A) costs fell to $2.3 million year over year.
• Cash, cash equivalents, and restricted cash totaled $31.5 million, with the company extending its cash runway into the fourth quarter of 2027.
• Management said it reached alignment with the U.S. Food and Drug Administration (FDA) on a smaller, lower-cost Phase 3 design for zervimesine (CT1812) in dementia with Lewy bodies (DLB).
• The company separately disclosed a Nasdaq notice that its stock traded below the $1.00 minimum bid price for 30 consecutive business days.
• For more context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Interested readers can also explore Trending AI Robots for AI-driven trading ideas.

Earnings Context and Why It Matters

Cognition Therapeutics is a clinical-stage biopharmaceutical company with no product revenue, so its quarterly earnings release matters less for the income statement than for the clinical and regulatory signals it carries. Investors use each report to gauge how quickly cash is being consumed and whether its lead candidate, zervimesine, is advancing toward a registrational trial. This quarter was particularly significant because management announced alignment with the FDA on a streamlined Phase 3 design in DLB, a step that clarifies the regulatory path after months of uncertainty. At the same time, the stock's decline below the $1.00 Nasdaq threshold adds a listing-compliance risk that sharpens the focus on capital raising and trial execution.

Reported Results

Cognition Therapeutics reported a third quarter 2026 net loss of $4.1 million, or $(0.04) per basic and diluted share, narrowing from a net loss of $4.9 million, or $(0.06) per share, in the year-ago quarter. The result beat the $(0.07) per share consensus estimate. R&D expenses rose to $5.1 million from $3.8 million, driven by higher trial activities with contract research organizations, while G&A expenses declined to $2.3 million from $2.6 million. Grant income climbed to $3.0 million from $1.2 million, which more than offset the wider operating loss. The company ended the quarter with $31.5 million in cash, cash equivalents, and restricted cash, plus $18.2 million in remaining National Institute on Aging (NIA) grant funds, and extended its expected cash runway into the fourth quarter of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Cognition Therapeutics, it offers a structured way to surface comparable opportunities across the biotechnology sector. Explore the AI Screener to refine your own market research.

Market Reaction and Investor Sentiment

The stock has been under sustained pressure, with shares trading near $0.68, down roughly 38% from the $1.10 level following the prior quarter's report. On November 3, 2026, the company received a deficiency letter from Nasdaq because its closing bid price had remained below the $1.00 minimum for 30 consecutive business days. The notice has no immediate effect on listing, and the company has 180 days, until May 3, 2027, to regain compliance. While the narrower-than-expected loss and FDA alignment are constructive developments, investor sentiment remains cautious, reflecting concerns about how the still-unfunded pivotal trial will be financed and the potential for further dilution. The per-share improvement also benefited from a larger share count, which has diluted existing holders.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the zervimesine program. Management said it has aligned with the FDA on a Phase 3 design in mild-to-moderate DLB, using a measure of hallucinations and delusions as the primary endpoint and a daily-living scale as a key secondary endpoint. The trial is expected to enroll fewer than half of the roughly 750 patients originally contemplated and to cost less than the approximately $150 million initially estimated.

However, the pivotal study remains unfunded, and the company is targeting a mid-2027 start. Investors should watch for news on financing, partnerships, or other capital-raising steps, as these will shape both dilution risk and the company's ability to execute the trial.

A separate catalyst is the START Phase 2 study of zervimesine in early Alzheimer's disease. That 545-patient trial is fully enrolled and funded with non-dilutive NIA capital, with top-line results expected in the second half of 2027 — timing that coincides closely with the projected end of the company's cash runway.

Finally, monitoring the bid price and any steps to restore Nasdaq compliance, such as a potential reverse stock split, will be important for assessing shareholder risk. All of these factors should be viewed in the context of the company's broader effort to advance a disease-modifying therapy while preserving its balance sheet.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations